The FDA objected twice before this GLP-1 supplement shipped. It is still on sale.

On 22 September 2026 the FDA published warning letter 731846, issued on 24 August 2026 to BioDrive, Inc. of 325 Hudson Street, New York, and addressed to its chief executive, Cory A. Henderson. One product is named: Evolv GLP-1 Biomimetic, a tablet sold direct to consumers. The dietary ingredient its label declares is Saccharomyces cerevisiae S288C EV-1 Peptide — a peptide produced by an engineered strain of baker's yeast.

The letter's reasoning runs in four steps. EV1-Peptide is a dietary ingredient under section 201(ff)(1)(F) of the Food, Drug and Cosmetic Act. It is also a new dietary ingredient under section 413(d), because, in the agency's words, "to the best of FDA's knowledge, there is no information demonstrating that EV1-Peptide was marketed as a dietary ingredient in the United States before October 15, 1994." A supplement containing a new dietary ingredient is adulterated under section 402(f)(1)(B) if there is inadequate information to give reasonable assurance that the ingredient does not present a significant or unreasonable risk of illness or injury. And shipping an adulterated supplement is prohibited by section 301(a).

The sentence the story turns on is this one: "You submitted two new dietary ingredient notifications (NDINs) to FDA in which we determined there was inadequate information to conclude that a dietary supplement containing EV1-Peptide would reasonably be expected to be safe." The letter adds that the agency "identified safety concerns due to potential toxicity, which raised concerns for adverse clinical consequences." BioDrive was given fifteen working days from receipt to say what it had done about it. All of this is the FDA's position after reading what the company sent. It is an allegation the company can contest, and we have not seen a response from it.

What makes this worth a post rather than a line in a list is the machinery it exposes, which almost nobody outside the supplement industry knows is there. The FDA does not approve dietary supplements, and it does not approve their ingredients. There is no approval to grant and therefore none to withhold. What the law asks for a new dietary ingredient is a notification: the manufacturer tells the agency, at least 75 days before marketing, what the ingredient is and why it believes the ingredient is reasonably expected to be safe. The agency reads it and may write back objecting. An objection is a letter. It does not suspend anything, seize anything or require a recall, and the company is free to file again — BioDrive filed twice — and, when the agency is still unsatisfied, free to ship regardless. Enforcement, if it comes, arrives afterwards and separately, as the adulteration charge above.

This site keeps insisting that approved, compounded, research-labelled and prohibited-in-sport are four different things. Here is a fifth, and it behaves like none of them. An approved drug had to produce its evidence before it could be sold at all. A compounded drug needs a prescriber and an identified patient. A research-labelled vial claims, dubiously, to sit outside the human-use framework altogether. A dietary supplement is sold openly, in retail packaging, with a nutrition panel, to anyone with a card — and in this case the safety review that the category's respectability rests on had already come back unfavourable, twice, before the first tablet shipped.

There is also a discrepancy in how this compound has been described, and it is not a small one. A Business Wire release put out for the launch on 3 September 2025 says the EV1 Peptide is derived from yeast hydrolysate "which is clinically demonstrated to activate the body's natural GLP-1 production" — that is, your own gut secretes more of the hormone. AgFunderNews, covering the launch on 6 October 2025, quotes cofounder Becca McCarthy describing "a GLP-1 and GIP receptor agonist oral supplement". Those are two different drugs. A receptor agonist binds the receptor itself, which is what semaglutide and tirzepatide do, and saying so is a drug claim. Prompting your body to release more of its own hormone is the structure-and-function language a supplement is permitted. The company's own science page currently sits between the two, saying the peptide "mimics your body's natural GLP-1 hormone" and works to "activate the body's GLP-1 pathways". These cannot all be describing the same thing, and which one is true is most of what decides what the product legally is.

The receptor-agonist version has a second question to answer. We made the point when orforglipron was approved: every GLP-1 receptor agonist except that one is a peptide, peptides are digested, and that is why the class is injected. An orally dosed peptide said to reach and bind the receptor runs straight into it. The company's answer, as reported by AgFunderNews, is that the peptide resists the DPP-4 enzyme and is carried inside the inactivated yeast, with a half-life of one to two days. We have not seen a pharmacokinetic study showing what an oral dose achieves in human blood, and the company's site cites none.

Now the part that will be overstated, so we will be exact about it. The published letter carries one violation heading and it is adulteration. There is no unapproved-new-drug charge under section 505(a), no misbranding charge, and no passage quoting disease claims from the website or anyone's social media — all of which are the agency's usual instruments against marketing of this kind, and all of which are absent here. The FDA's complaint, as written, is about the safety dossier rather than the advertising. Anyone reporting this as the FDA calling the product an illegal drug is adding something the document does not say.

What we could check ourselves, we did. As of today the product is still for sale on the company's own store at $148.00 for 60 tablets, or $125.80 on a four-week subscription, at a suggested two to three tablets a day. The page advertises "up to 12+ lbs lost in 8 weeks" and roughly 750 fewer calories consumed per day, from an eight-week randomised controlled study. It names no journal for that study and we could not find one. Beneath all of it sits the standard disclaimer that the statements have not been evaluated by the Food and Drug Administration and that the product is not intended to diagnose, treat, cure or prevent any disease — printed under a product named for a hormone and sold for weight loss. Note also the dates: the letter was issued on 24 August and published on 22 September, so the fifteen working days had run out before anyone outside the company and the agency could have known there was a letter at all.

Our index supplies the scale the letter does not. As of today we hold confirmed listings for tirzepatide from 32 of the vendors we read and semaglutide from 27, sold per milligram as a powder under a research label. For orforglipron, the approved oral GLP-1, we hold one. This tablet is a fourth thing again: a GLP-1 product with a retail price, a nutrition panel and a shipping address, requiring neither a prescription nor the pretence of a laboratory. We do not carry it and will not. Our index prices vials of named compounds per milligram, and a consumer supplement is not that.

Four things this does not establish. It is not a finding that the product is unsafe — the agency said the information submitted was inadequate to conclude that it is reasonably expected to be safe, which is a statement about a dossier rather than a demonstrated harm, and the two are reported as the same sentence constantly. It is not a finding about whether it works, because the notification process does not ask that. It is not a recall, and nothing has been seized or withdrawn. And it has no connection to the July advisory committee recommendation on the 503A bulks list: a dietary supplement is not a compounded drug, this peptide was never in that process, and that process still requires rulemaking before it changes anything.